Article
Oncology
Hirofumi Mukai, Yukari Uemura, Hiromitsu Akabane, Takanori Watanabe, Youngjin Park, Masato Takahashi, Yoshiaki Sagara, Reiki Nishimura, Tsutomu Takashima, Tomomi Fujisawa, Yasuo Hozumi, Takuya Kawahara
Summary: The study demonstrates that S-1 is non-inferior to anthracycline-containing regimens as first-line chemotherapy for patients with HER2-negative metastatic breast cancer. S-1 may be considered a new treatment option in this setting.
BRITISH JOURNAL OF CANCER
(2021)
Article
Oncology
Wanjing Chen, Qian Tu, Yanfei Shen, Kejun Tang, Mengying Hong, Yong Shen
Summary: The study compared the efficacy of sequential and concurrent regimens of anthracyclines and taxanes in operable breast cancer patients. It was found that for operable breast cancer patients, the sequential regimen did not significantly improve disease-free survival or overall survival compared to the concurrent regimen. However, in node-positive patients, the sequential regimen showed a slight advantage in disease-free survival.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Medicine, General & Internal
Gaoming Liao, Zedong Jiang, Yiran Yang, Cong Zhang, Meiting Jiang, Jiali Zhu, Liwen Xu, Aimin Xie, Min Yan, Yunpeng Zhang, Yun Xiao, Xia Li
Summary: The study found that HRD prolongs the chemotherapy failure-free interval in TNBC patients and improves patient prognosis. By analyzing both HRD status and ACT response, a distinct TNBC subtype (ACT-S&HR-P) was identified with higher tumor lymphocyte infiltration, IFN-gamma activity, and NK cell levels, indicating elevated immune activation.
Article
Oncology
Alejandra Bernardini, Marta Duenas, Maria Cruz Martin-Soberon, Carolina Rubio, Cristian Suarez-Cabrera, Raquel Ruiz-Palomares, Ester Munera-Maravilla, Sara Lazaro, Iris Lodewijk, Daniel Rueda, David Gomez-Sanchez, Teresa Alonso-Gordoa, Javier Puente, Alvaro Pinto, Pilar Gonzalez-Peramato, Carlos Aguado, Mercedes Herrera, Flora Lopez, Victor M. G. Martinez, Lucia Morales, Daniel Castellano, Jesus M. Paramio, Guillermo de Velasco
Summary: Metastatic urothelial carcinoma is a difficult-to-cure disease with limited treatment options. Vinflunine has shown some improvement in overall survival and is still used for patients who are refractory to chemotherapy and immunotherapy. However, there is a lack of biomarkers to identify responding patients and alternative therapies after treatment failure.
Article
Oncology
Lanqi Ren, Ning Ren, Yu Zheng, Yibei Yang, Qiaoping Xu
Summary: This study analyzed the cost-effectiveness of neratinib plus capecitabine (N+C) and lapatinib plus capecitabine (L+C) in HER2-positive metastatic breast cancer. The results showed that N+C was dominant in most scenarios, providing an improvement of 0.17 quality-adjusted life-years (QALYs) and reducing costs compared to L+C. The ICER was below the willingness to pay threshold, indicating that N+C is a cost-effective third-line treatment option for HER2-positive metastatic breast cancer patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina, Peter Kabos, Marie Wood, Anthony Elias, Lavanya Kondapalli, Cathy J. Bradley, Jennifer R. Diamond
Summary: This study investigated the impact of anthracycline plus taxane (ATAX) regimens and non-anthracycline-containing, taxane-based (TAX) regimens on the survival rate of older women with triple-negative breast cancer (TNBC). The results showed that adjuvant chemotherapy improved cancer-specific survival (CSS) and overall survival (OS) in TNBC patients. There was a trend towards better outcomes with ATAX for patients with more than 4 positive lymph nodes.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Sakar Wahby, Lola Fashoyin-Aje, Christy L. Osgood, Joyce Cheng, Mallorie H. Fiero, Lijun Zhang, Shenghui Tang, Salaheldin S. Hamed, Pengfei Song, Rosane Charlab, Sarah E. Dorff, Tiffany K. Ricks, Kimberly Barnett-Ringgold, Jeannette Dinin, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Laleh Amiri-Kordestani, Julia A. Beaver
Summary: FDA granted accelerated approval to Sacituzumab Govitecan-hziy for the treatment of metastatic triple-negative breast cancer. Data showed an objective response rate of 33.3% and a median duration of response of 7.7 months, supporting the approval.
CLINICAL CANCER RESEARCH
(2021)
Article
Medicine, General & Internal
Eun Kyo Joung, Ji Hyun Yang, Sooeun Oh, Se Jun Park, Jieun Lee
Summary: This study analyzed the role of single-agent maintenance chemotherapy after cisplatin-doublet chemotherapy for anthracycline-and taxane-resistant metastatic breast cancer patients. The results showed that patients who switched to single-maintenance chemotherapy after showing clinical benefit during cisplatin-doublet therapy had superior survival outcomes compared to those who continued doublet regimen or suspended chemotherapy.
KOREAN JOURNAL OF INTERNAL MEDICINE
(2021)
Article
Oncology
Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, Jin-Hee Ahn, Joohyuk Sohn, Jin Seok Ahn, Moon Hee Lee, Jee Hyun Kim, Kyung Eun Lee, Hyo Jung Kim, Si -Young Kim, Yeon Hee Park, Chan-Young Ock, Kyung-Hun Lee, Sae-Won Han, Sung-Bae Kim, Young Hyuck Im, Hyun Cheol Chung, Do-Youn Oh, Seock-Ah Im
Summary: This single-arm phase II trial investigated the efficacy and safety of S-1 plus oxaliplatin (SOX) in metastatic breast cancer patients. The study showed that SOX regimen is a reasonable option for patients previously treated with anthracyclines and taxanes. The ORR of the SOX regimen was 38.5% with a median TTP of 6.0 months.
CANCER RESEARCH AND TREATMENT
(2023)
Article
Oncology
Anna R. Schreiber, Jodi Kagihara, Megan Eguchi, Peter Kabos, Christine M. Fisher, Elisabeth Meyer, Elizabeth Molina, Lavanya Kondapalli, Cathy J. Bradley, Jennifer R. Diamond
Summary: The study evaluated the effect of adjuvant anthracycline + taxane (ATAX) versus taxane-based (TAX) chemotherapy on cancer-specific (CSS) and overall survival (OS) in older patients with node-negative TNBC. The results showed that while adjuvant chemotherapy improved clinical outcomes, the administration of ATAX compared to TAX was associated with inferior 3-year OS and CSS in this patient population.
BREAST CANCER RESEARCH AND TREATMENT
(2022)
Article
Oncology
Luc Cabel, Matthieu Carton, Barbara Pistilli, Florence Dalenc, Laurence Vanlemnens, Christelle Levy, William Jacot, Michel Debled, Agnes Loeb, Audrey Hennequin, Thibault De la Motte Rouge, Lilian Laborde, Carine Laurent, E. Chamorey, Damien Parent, Thierry Petit, Marie-Ange Mouret-Reynier, Mario Campone, Genevieve Perrocheau, Claire Labreveux, Thomas Bachelot, Mathieu Robain, Florence Lerebours
Summary: This study aimed to identify predictive factors of outcome after third-or fourth-line chemotherapy in metastatic triple-negative breast cancer patients. Factors such as PFS, number of metastatic sites, and metastasis-free interval were found to influence overall survival, with prognostic nomograms achieving a moderate level of accuracy.
Article
Oncology
Huikun Zhang, Yawen Zhao, Xiaoli Liu, Li Fu, Feng Gu, Yongjie Ma
Summary: C7, identified as a potential biomarker for breast cancer, is associated with poor prognosis, specific subtypes, and bone metastasis risk. Moreover, high expression of C7 may indicate insensitivity to TE-based chemotherapy.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Juan Zhang, Lu Yao, Yiqiang Liu, Tao Ouyang, Jinfeng Li, Tianfeng Wang, Zhaoqing Fan, Tie Fan, Benyao Lin, Yuntao Xie
Summary: This study found that in BRCA1/2-mutated triple-negative breast cancer, adding carboplatin to the standard A-T chemotherapy regimen can improve survival rates for patients.
INTERNATIONAL JOURNAL OF CANCER
(2021)
Article
Oncology
B. Xu, T. Sun, Q. Zhang, P. Zhang, Z. Yuan, Z. Jiang, X. Wang, S. Cui, Y. Teng, X-C Hu, J. Yang, H. Pan, Z. Tong, H. Li, Q. Yao, Y. Wang, Y. Yin, P. Sun, H. Zheng, J. Cheng, J. Lu, B. Zhang, C. Geng, J. Liu, K. Shen, S. Yu, L. Tang, R. Qiu
Summary: The combination therapy of utidelone plus capecitabine significantly improved overall survival, progression-free survival, and overall response rate in heavily-pretreated patients with metastatic breast cancer, with no new safety concerns.
ANNALS OF ONCOLOGY
(2021)
Article
Pharmacology & Pharmacy
Min Sun, Xiaoxiao Liu, Lingyun Xia, Yuying Chen, Li Kuang, Xinsheng Gu, Tian Li
Summary: A nine-lncRNA prognostic risk score model was developed to predict distant relapse-free survival of patients with HER2-negative breast cancer following taxane and anthracycline-based neoadjuvant chemotherapy. This model showed robust predictive power compared to other prognostic markers and could differentiate survival probability between different expression levels of the lncRNAs.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Oncology
Arvind Arora, Tarek M. A. Abdel-Fatah, Devika Agarwal, Rachel Doherty, Deborah L. Croteau, Paul M. Moseley, Khalid Hameed, Andrew Green, Mohammed A. Aleskandarany, Emad A. Rakha, Karl Patterson, Graham Ball, Stephen Y. T. Chan, Ian O. Ellis, Vilhelm A. Bohr, Helen E. Bryant, Srinivasan Madhusudan
Article
Oncology
Wilbert Zwart, Koend. Flach, Bharath Rudraraju, Tarek M. A. Abdel-Fatah, Ondrej Gojis, Sander Canisius, David Moore, Ekaterina Nevedomskaya, Mark Opdam, Marjolein Droog, Ingrid Hofland, Steve Chan, Jacqui Shaw, Ian O. Ellis, R. Charles Coombes, Jason S. Carroll, Simak Ali, Carlo Palmieri
CLINICAL CANCER RESEARCH
(2016)
Article
Oncology
Tarek M. A. Abdel-Fatah, Stephanie E. B. McArdle, Devika Agarwal, Paul M. Moseley, Andrew R. Green, Graham R. Ball, A. Graham Pockley, Ian O. Ellis, Robert C. Rees, Stephen Y. T. Chan
CLINICAL CANCER RESEARCH
(2016)
Article
Oncology
Nouf Alsubhi, Fiona Middleton, Tarek M. A. Abdel-Fatah, Peter Stephens, Rachel Doherty, Arvind Arora, Paul M. Moseley, Stephen Y. T. Chan, Mohammed A. Aleskandarany, Andrew R. Green, Emad A. Rakha, Ian O. Ellis, Stewart G. Martin, Nicola J. Curtin, Srinivasan Madhusudan
MOLECULAR ONCOLOGY
(2016)
Article
Oncology
P. Vuylsteke, M. Huizing, K. Petrakova, R. Roylance, R. Laing, S. Chan, F. Abell, S. Gendreau, I. Rooney, D. Apt, J. Zhou, S. Singel, L. Fehrenbacher
ANNALS OF ONCOLOGY
(2016)
Review
Pathology
Jeremy St John Thomas, Elena Provenzano, Louise Hiller, Janet Dunn, Clare Blenkinsop, Louise Grybowicz, Anne-Laure Vallier, Ioannis Gounaris, Jean Abraham, Luke Hughes-Davies, Karen McAdam, Stephen Chan, Rizvana Ahmad, Tamas Hickish, Stephen Houston, Daniel Rea, Carlos Caldas, John M. S. Bartlett, David Allan Cameron, Richard Laurence Hayward, Helena Margaret Earl
Article
Oncology
Tarek M. A. Abdel-Fatah, Robert C. Rees, A. Graham Pockley, Paul Moseley, Graham R. Ball, Stephen Y. T. Chan, Ian O. Ellis, Amanda K. Miles
Article
Oncology
Nouf Al-Subhi, Reem Ali, Tarek Abdel-Fatah, Paul M. Moseley, Stephen Y. T. Chan, Andrew R. Green, Ian O. Ellis, Emad A. Rakha, Srinivasan Madhusudan
BREAST CANCER RESEARCH AND TREATMENT
(2018)
Article
Biochemistry & Molecular Biology
Andrew Tutt, Holly Tovey, Maggie Chon U. Cheang, Sarah Kernaghan, Lucy Kilburn, Patrycja Gazinska, Julie Owen, Jacinta Abraham, Sophie Barrett, Peter Barrett-Lee, Robert Brown, Stephen Chan, Mitchell Dowsett, James M. Flanagan, Lisa Fox, Anita Grigoriadis, Alexander Gutin, Catherine Harper-Wynne, Matthew Q. Hatton, Katherine A. Hoadley, Jyoti Parikh, Peter Parker, Charles M. Perou, Rebecca Roylance, Vandna Shah, Adam Shaw, Ian E. Smith, Kirsten M. Timms, Andrew M. Wardley, Gregory Wilson, Cheryl Gillett, Jerry S. Lanchbury, Alan Ashworth, Nazneen Rahman, Mark Harries, Paul Ellis, Sarah E. Pinder, Judith M. Bliss
Article
Oncology
Tarek M. A. Abdel-Fatah, Reuben J. Broom, Jun Lu, Paul M. Moseley, Baiqu Huang, Lili Li, Suling Liu, Longxin Chen, Runlin Z. Ma, Wenming Cao, Xiaojia Wang, Yan Li, Jo K. Perry, Mohammed Aleskandarany, Christopher C. Nolan, Emad A. Rakha, Peter E. Lobie, Stephen Y. T. Chan, Ian O. Ellis, Le-Ann Hwang, David P. Lane, Andrew R. Green, Dong-Xu Liu
BRITISH JOURNAL OF CANCER
(2019)
Article
Oncology
Katia A. Mesquita, Muslim Alabdullah, Michaela Griffin, Michael S. Toss, Tarek M. A. Abdel Fatah, Adel Alblihy, Paul Moseley, Stephen Y. T. Chan, Emad A. Rakha, Srinivasan Madhusudan
GYNECOLOGIC ONCOLOGY
(2019)
Article
Obstetrics & Gynecology
M. L. Alabdullah, D. A. Ahmad, P. Moseley, S. Madhusudan, S. Chan, E. Rakha
JOURNAL OF OBSTETRICS AND GYNAECOLOGY
(2019)
Meeting Abstract
Oncology
T. M. Abdel-Fatah, G. R. Ball, I. O. Ellis, A. Chan, S. Y. Chan
Article
Oncology
Alessandra Franzetti Pellanda, Berardino De Bari, Elisabeth Deniaud-Alexandre, Marco Krengli, Paul Van Houtte, Antonella Richetti, Salvador Villa, Hadassah Goldberg, Ewa Szutowicz-Zielinska, Michel Bolla, Heidi Rutten, Marc Van Eijkeren, Philip Poortmans, Guido Henke, Yavuz Anacak, Steve Chan, Christine Landmann, Carine Kirkove, Luciano Scandolaro, Jacques Bernier, Rene-Olivier Mirimanoff, Mahmut Ozsahin
CHINESE JOURNAL OF CANCER RESEARCH
(2017)
Article
Oncology
B. Pistilli, T. Pluard, A. Urruticoechea, D. Farci, A. Kong, T. Bachelot, S. Chan, H. S. Han, G. Jerusalem, P. Urban, D. Robinson, S. L. Mouhaer, E. D. Tomaso, C. Massacesi, C. Saura
BREAST CANCER RESEARCH AND TREATMENT
(2018)